[{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Advanced Biofuels","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Norbaeocystin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"PsyBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"PsyBio Therapeutics \/ Advanced Biofuels","highestDevelopmentStatusID":"6","companyTruncated":"PsyBio Therapeutics \/ Advanced Biofuels"},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"PsyBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PsyBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"PsyBio Therapeutics \/ PsyBio","highestDevelopmentStatusID":"4","companyTruncated":"PsyBio Therapeutics \/ PsyBio"},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"PsyBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"PsyBio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PsyBio Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by PsyBio Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BIO CEO & Investor
                          Not Confirmed
                          BIO CEO & Investor
                          Not Confirmed

                          Details : PsyBio is tech transferring first two of its lead compounds, psilocybin and norbaeocystin, into process development and scaled manufacturing. This filing increases PsyBio's licensed patent portfolio to 4 pending provisional patents and 1 pending non-prov...

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 12, 2021

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          BIO CEO & Investor
                          Not Confirmed
                          BIO CEO & Investor
                          Not Confirmed

                          Details : Under the Amended Agreement, the Jones Lab plans to develop elite microbes capable of efficient production of a range of medically-relevant alkaloids. The compounds of interest, Psilocybin, originate from a variety of plants and fungi, including magic mu...

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 26, 2021

                          Lead Product(s) : Psilocybine

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Recipient : Miami University Broaden

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          RNA Therapeutics
                          Not Confirmed
                          RNA Therapeutics
                          Not Confirmed

                          Details : Norbaeocystin is an analogue of psilocybin and is not a controlled substance. The Company has commenced Phase I of this process, including analytical chemistry technical transfer to establish detection methods for fermentation products and key feedstocks...

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 23, 2021

                          Lead Product(s) : Norbaeocystin

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase I

                          Sponsor : Advanced Biofuels

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank